« Back to Farmacia Journal 5/2016

PHARMACOLOGICAL TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS-WHERE ARE WE?

CARMEN ADELLA SIRBU ^1#, EMILIA FURDU-LUNGUT ^1#, CRISTINA FLORENTINA PLESA ^1#, ALINA CRENGUȚA NICOLAE ^2#*, CRISTINA MANUELA DRAGOI ^2#

Download Full Article PDF

Multiple sclerosis is a chronic disease of the central nervous system, characterized by inflammation, demyelination and neurodegeneration. The cause of the disease is not known, but the mechanism is assumed to be an auto-immune one. For the disease occurrence, two conditions are necessary: genetic predisposition and certain environmental factors acting as activating factors. The total costs of this disease are high, as it affects mainly young people aged 20 - 40, the evolution is long, requiring medical care, expensive treatments, recovery, in parallel with the loss of productivity at a certain moment, during the disease evolution. Thus, the interest for an efficient, affordable and safe medication is of high interest. Today, we have two categories of drugs modifying the evolution of this diseases as well as guides of diagnosis and treatment that are periodically changing, according to the results of the clinical studies and of evidence-based medicine. As such, we aimed at pointing out the main approved to treat the relapsing- remitting form of multiple sclerosis (RRMS).